|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM250050382 |
| 003 |
DE-627 |
| 005 |
20231224154911.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2015 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2015.05.012
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0833.xml
|
| 035 |
|
|
|a (DE-627)NLM250050382
|
| 035 |
|
|
|a (NLM)26083948
|
| 035 |
|
|
|a (PII)S1521-6616(15)00186-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Esmaeilzadeh, Hossein
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Aspirin desensitization for patients with aspirin-exacerbated respiratory disease
|b A randomized double-blind placebo-controlled trial
|
| 264 |
|
1 |
|c 2015
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.12.2015
|
| 500 |
|
|
|a Date Revised 24.09.2015
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2015 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The effect of aspirin desensitization (AD) on immunologic profile of patients with AERD has been poorly understood. This study is aimed at investigating the effect of AD on clinical and immunological markers of patients with AERD. This randomized double-blind placebo-controlled trial comprised 34 adult patients (67.6% female) with chronic rhinosinusitis, nasal polyps, and aspirin-intolerant asthma. The active group underwent AD over a 2-day period with increasing doses of aspirin (60, 125, 325, and 625 mg), followed by receiving aspirin 625 mg twice daily for 6 months. Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months (7.5 ± 3.5 vs. 10.6 ± 3.8 and 9.3 ± 2.0 vs. 11.0 ± 3.1, respectively, all p < 0.05). However, no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Aspirin-intolerant asthma
|
| 650 |
|
4 |
|a Desensitization
|
| 650 |
|
4 |
|a Interferon-gamma
|
| 650 |
|
4 |
|a Interleukin-10
|
| 650 |
|
4 |
|a Quality of life
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents, Non-Steroidal
|2 NLM
|
| 650 |
|
7 |
|a IL10 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Transforming Growth Factor beta
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 650 |
|
7 |
|a Aspirin
|2 NLM
|
| 650 |
|
7 |
|a R16CO5Y76E
|2 NLM
|
| 700 |
1 |
|
|a Nabavi, Mohammad
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aryan, Zahra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arshi, Saba
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bemanian, Mohammad Hassan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fallahpour, Morteza
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mortazavi, Negar
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 160(2015), 2 vom: 21. Okt., Seite 349-57
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:160
|g year:2015
|g number:2
|g day:21
|g month:10
|g pages:349-57
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2015.05.012
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 160
|j 2015
|e 2
|b 21
|c 10
|h 349-57
|